Trial Profile

A trial of VAL 083 in patients with non-small cell lung cancer

Status: Planning

Phase of Trial: Phase IV

Latest Information Update: 07 Sep 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dianhydrogalactitol (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use
Sponsors Del Mar Pharmaceuticals; Guangxi Wuzhou Pharmaceutical

Most Recent Events

02 Sep 2015 According to a DelMar pharmaceuticals media release, details of this trial will be presented at the 16th World Conference on Lung Cancer.
15 Jun 2015 This study will be covered in a presentation by DelMar Pharmaceuticals at The World NSCLC Summit, according to a company media release.
09 Oct 2014 Following successful in vivo studies of VAL 083 in models of NSCLC, DelMar Pharmaceuticals and Guangxi Wuzhou Pharmaceuticals are expecting to conduct a clinical trial of VAL 083 in patients in China, according to a media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com